PacBio management commentary: Stronger instrument sales drive 6% revenue growth in Q3 2026
PACB•PacBio reported third-quarter 2026 revenue of $40.6 million, up 6% year over year, as instrument revenue rose 16% to $13.2 million. Non-GAAP gross margin fell to 36% from 42%, while non-GAAP operating expenses declined 13% to $47 million.
1. Quarterly results
PacBio attributed third-quarter 2026 revenue growth of 6% to $40.6 million to stronger instrument sales. Instrument revenue rose 16% to $13.2 million, while consumables revenue fell to $20.8 million from $21.3 million; non-GAAP gross margin declined to 36% from 42%, and non-GAAP operating expenses decreased 13% to $47 million.
